Foghorn Therapeutics Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Foghorn Therapeutics Inc. (FHTX) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$14.05 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-06
- Foghorn Therapeutics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was $6.79M, a 21.81% increase year-over-year.
- Foghorn Therapeutics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was $5.57M.
- Foghorn Therapeutics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$1.08M.
- Foghorn Therapeutics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2021-03-31 was -$26.35M.
- Foghorn Therapeutics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $26.96M.
- Foghorn Therapeutics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$24.88M, a 188.48% decline from fiscal 2023.
- Foghorn Therapeutics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was $28.12M.
- Foghorn Therapeutics Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$48.95M, a 686.82% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$14.05M 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $6.79M 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $26.96M 10-K · filed 2026-03-11 | |||
| 2025-09-30 | $35.42M 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | $18.66M 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | $5.57M 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | -$24.88M 10-K · filed 2026-03-11 | |||
| 2024-09-30 | -$22.66M 10-Q · filed 2025-11-05 | |||
| 2024-06-30 | $58.61M 10-Q · filed 2025-08-05 | |||
| 2024-03-31 | -$1.08M 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | $28.12M 10-K · filed 2025-03-06 | |||
| 2022-12-31 | -$48.95M 10-K · filed 2024-03-07 | |||
| 2021-12-31 | $8.34M 10-K · filed 2023-03-09 | |||
| 2021-03-31 | -$26.35M 10-Q · filed 2021-05-11 | |||
| 2020-12-31 | $77.27M 10-K/A · filed 2022-08-09 | |||
| 2020-09-30 | $59.64M 10-Q · filed 2020-12-04 | |||
| 2020-03-31 | -$11.54M 10-Q · filed 2021-05-11 | |||
| 2019-12-31 | -$23.33M 10-K · filed 2021-03-18 | |||
| 2019-09-30 | -$18.52M 10-Q · filed 2020-12-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |